Revumenib
As of the edition of 20 October 2026, Revumenib is a small molecule: marketed, first approved in 2024 (US); acts on KMT2A and MEN1; US protection ends in 2037.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Revuforj
- First approved
- 15 November 2024 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Syndax Pharmaceuticals
- Registered trials
- 27, 3 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Digestive system; Infections
US protection
US protection ends in 2037.
The last listed US drug-substance patent ends in 2037. The application that gives this date is held by Syndax Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Revumenib.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 11 | 2 | 7 | 2 |
| Phase 2 | 12 | 0 | 11 | 1 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Syndax Pharmaceuticals | Originator and Lead sponsor of trials | 2024 to now |